News >

Biosimilar Filgrastim Would Lower Medicare Out-of-Pocket Expenses

Wayne Kuznar
Published: Tuesday, Dec 18, 2018

Gary Puckrein, PhD

Gary Puckrein, PhD

Out-of-pocket expenditures are substantially less among Medicare beneficiaries with breast cancer undergoing chemotherapy who receive prophylaxis for febrile neutropenia with a filgrastim biosimilar (filgrastim-sndz; Zarxio) as opposed to the reference product.

“By weighted average, a beneficiary’s out-of-pocket responsibility for filgrastim-sndz was lower than that for reference filgrastim (.94 versus .45), creating a weighted average cost saving per claim of .51,” the investigators concluded in their poster. “Extrapolated to 100,000 beneficiaries (1 million claims), the overall out-of-pocket saving for administration of filgrastim-sndz rather than reference filgrastim would be around .5 million.”
Puckrein G, Xu L, Ryan A, et al. Potential Medicare beneficiary out-of-pocket cost reductions through use of biosimilar filgrastim-sndz over reference filgrastim among breast cancer patients: A simulation model analysis.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Addressing Uncertainties in Oncology BiosimilarsApr 30, 20201.5
Publication Bottom Border
Border Publication